The mammalian SWI/SNF complexes mediate ATPdependent chromatin remodeling processes that are critical for differentiation and proliferation. Not surprisingly, loss of SWI/SNF function has been associated with malignant transformation, and a substantial body of evidence indicates that several components of the SWI/SNF complexes function as tumor suppressors. This review summarizes the evidence that underlies this conclusion, with particular emphasis upon the two catalytic subunits of the SWI/SNF complexes, BRM, the mammalian ortholog of SWI2/SNF2 in yeast and brahma in Drosophila, and Brahma-related gene-1 (BRG1).
subset of the SWI genes are identical to those identified in the SNF screen, and those genes that are involved both in mating-type switching and sucrose fermentation have come to be known as SWI/SNF genes Wolffe, 1994) . Although SWI/SNF is a relatively rare enzyme in yeast, present at only 100-500 copies per nucleus (Cote et al., 1994) , it has been estimated that 5-7% of all yeast genes require SWI/SNF activity for expression (Sudarsanam et al., 2000; Zraly et al., 2006; Monahan et al., 2008) . Estimates of the role of SWI/SNF in the control of Drosophila gene expression range from 1-2% of the genome (based upon inactivation of SNR1/ SNF5) to essentially the whole genome (based upon estimated chromosomal loss of RNA polymerase II in cells that express a dominant-negative brahma allele) (Armstrong et al., 2002) . In yeast, the SWI/SNF complex can both promote and suppress gene expression (Zhang et al., 2007) ; about a third of the yeast genes regulated by SWI/SNF are suppressed (Sudarsanam et al., 2000) .
The role of SWI/SNF genes in the differentiation of multicellular organisms was initially demonstrated by characterization of the Drosophila homeotic gene brahma or BRM (Tamkun, 1995) . This gene was identified in screens for dominant suppressors of Polycomb mutations (Tamkun et al., 1992) . BRM is also a transcriptional activator of Hox genes and therefore required for the specification of body segment identities (Armstrong et al., 2002) . Sequence analysis established that BRM is a member of the Drosophila trithorax gene group and thus likely to be involved in chromatin remodeling, and BRM is homologous to yeast SWI2/SNF2 (Tamkun, 1995; Papoulas et al., 1998) . The Drosophila BRM amino sequence is 56% identical and 72% similar to the human BRM protein (Elfring et al., 1994) .
Drosophila BRM-containing complexes bind the trithorax group Zeste to activate nucleosomal templates (Kal et al., 2000) . Three other Drosophila trithorax genes have been identified as SWI/SNF homologs, which, in Drosophila, are known as BRM-associated proteins or BAPs: SNR1/BAP45 is homologous to the mammalian BAF47 and to yeast SNF5 (Dingwall et al., 1995) ; Osa is homologous to the mammalian BAF250 and to yeast SWI1 (Collins et al., 1999; Nie et al., 2000) ; and Moira/ BAP155 is homologous to the mammalian BAF155/ BAF170 and to the yeast SWI3 (Neely and Workman, 2002) (Table 1) . Elucidation of the role of these genes in pattern formation established a functional link between SWI/SNF activity and development in multicellular organisms.
Composition of the SWI/SNF complexes
Mammalian cells express BRM as well as a closely related protein called Brahma-related gene-1 (BRG1). Human BRG1 is approximately 74% identical to human BRM (Khavari et al., 1993) , 52% identical to Drosophila BRM and 33% identical to yeast SWI2/ SNF2 (Fry and Peterson, 2001 ). The mammalian SWI/ SNF complexes contain, in addition to BRM or BRG1, 8-10 subunits, which are referred to as BRM-or BRG1-associated factors or BAFs (Wang et al., 1996a, b) . Table 1 lists all of the well-characterized mammalian BAFs and shows their non-vertebrate orthologs, the Drosophila BAPs and yeast SWI/SNF gene family members. Two features of Table 1 warrant emphasis. First, no single mammalian SWI/SNF complex will contain all of these subunits; and second, not all mammalian SWI/SNF subunits have invertebrate orthologs, suggesting that the mammalian SWI/SNF complexes are structurally and, perhaps functionally, more diverse than those of yeast or flies. The yeast SWI/SNF complex exhibits an apparent molecular mass of 1.14 MDa , whereas the mammalian SWI/SNF complex has an apparent molecular mass of E2 MDa. The stoichiometry of the SWI/SNF complexes has not been unambiguously resolved, but it is most likely that no single complex contains all of the subunits listed in Table 1 . Mammalian BAF proteins are conventionally identified by their molecular size; hence BAF47 refers to a BRG1-associated protein with an apparent molecular mass of 47 kDa. BAF47 has been shown to be homologous to both SNF5 in yeast and SNR1 in Drosophila. In parallel, BAF47 was cloned as a gene that is required for lentiviral integration and was thus originally referred to as INI1 (Kalpana et al., 1994) .
It is believed that an individual SWI/SNF complex contains either BRM or BRG1, but not both (Wang et al., 1996a, b) , such that BRM/BAF complexes are structurally distinct from BRG1/BAF complexes ( Figure 1) . The extent to which these complexes are functionally distinct is a topic of active investigation. The BRG1-containing complexes are further divided into those that contain the BAF250 (or OSA protein) or the BAF180 protein (Wang, 2003) , which is thought to be a fusion protein of three separate RSC yeast proteins . BAF180 is the mammalian ortholog of Drosophila polybromo (Table 1) , and the polybromocontaining SWI/SNF complex has been designated as PBAF, to distinguish it from the BAF250-containing BRM/BAF and BRG1/BAF complexes (Figure 1 ). Several other complexes have been identified that contain BRG1 and a subset of SWI/SNF factors. These complexes include the WINAC complex, which contains the Williams syndrome transcription factor plus proteins involved in DNA replication and transcriptional elongation (Aoyagi, 2005 #3; Kitagawa, 2003 #1) , the NUMAC complex, which contains coactivator-associated arginine methyltransferase 1 (Xu, 2004 #801) , and two repressor complexes that collaborate with Kap1 or mSin3A (Underhill, 2000 #7) to recruit histone deacetylases (for review see Trotter and Archer (2008) ). Recently, a new complex has been discovered; it is in low abundance and contains an extra subunit, ENL, that was conserved between human and yeast SWI/ SNF (Nie et al., 2003) . Interestingly, ENL is a fusion Figure 1 The different domains that are contained in BRG1 and BRM. Each of these proteins contain an Rb binding, ATPase and Bromo domains. Despite these similarities, BRG1 and BRM are only 75% similar at the proteins. BRM differs as it has a poly q section that codes B33 repeating glutamine residues. BAF250A  ARID1A  SWI1  OSA  BAF250B  ARID1B  BAF200  ARID2  BAP170  BRM  SMARCA2  SWI2/SNF2  BRM  BRG1  SMARCA4  SWI2/SNF2  BRM  BAF180  PBRM1  RSC1  Moira/BAP155  BAF170  SMARCC2  SWI3  Moira/BAP155  BAF155  SMARCC1  SNF12  BAP60  BAF60A  SMARCD1  SNF12  BAP60  BAF60B  SMARCD2  SNF12  BAP60  BAF60C  SMARCD3  BAF57  SMARCE1  Dalao/BAP111  BAF53A  ACTL6A  BAP55  BAF53B  ACTL6B  ARP4  BAF47  SMARCB1  SNF5  SNR1 Although some components are conserved across species, others can only uniquely be found in the higher order mammalian species. (Kruger et al., 1995; Bortvin and Winston, 1996) . A number of elegant biochemical studies have been carried out to define the functions of SWI/SNF proteins in yeast and multicellular organisms (Hirschhorn et al., 1992; Kwon et al., 1994; Peterson and Tamkun, 1995; Tamkun, 1995; Peterson, 1998) . These analyses revealed that the SWI/SNF proteins function as ATP-dependent chromatin-remodeling complexes. Several models have been proposed to account for the ability of SWI/SNF to modify chromatin structure (Peterson and Workman, 2000; Hassan et al., 2001) . Alternative models include ATP-dependent movement of histone octamers in cis along the DNA, transfer of histone octamers from one nucleosomal array to another or replacement of nucleosomal histones (Smith and Peterson, 2005; Saha et al., 2006) . Further studies revealed that nucleosome remodeling by the yeast SWI/SNF is bidirectional along the DNA, resulting in a continuous positional re-distribution around a characteristic distance of motion of approximately 28 bp (Shundrovsky et al., 2006) . The net result is an altered structure that is hypersensitive to nuclease digestion and exhibits increased affinity for transcription factors (Schnitzler et al., 1998) and basal transcriptional machinery, such as the TATA box-binding protein, TBP . Such observations inform the prevailing view that SWI/SNF complexes regulate gene expression, at least in part, by inducing a nucleosome conformation that is more accessible to the transcriptional machinery. The energy for SWI/SNF-mediated chromatin remodeling is transduced by the catalytic subunit, BRM or BRG1, both of which have DNA-dependent ATPase activity (Muchardt and Yaniv, 1999a; Hassan et al., 2001) . It was initially assumed that the intact SWI/SNF complex was required for chromatin remodeling. However, this assumption has been challenged by the observation that both BRG1 and BRM have remodeling activity in the absence of other subunits (Phelan et al., 1999) . Addition of other core subunits, such as BAF47, BAF155 and BAF170, increases remodeling activity to a level comparable with that of the whole SWI/SNF complex, indicating that the entire complex is not absolutely necessary for chromatin remodeling, at least in vitro.
Mammalian BRM and BRG1 share approximately 75% identity at the amino-acid level. The first 60 amino acids of BRG1 and BRM are divergent. BRM contains a polyQ expansion repeat that encodes approximately 33 glutamines (216-254 aa), whereas BRG1 contains no such repeat (Figure 2 ). The length of the BRM polyQ repeat varies among cell lines, but it is not known if the expansion of this repeat affects BRM function (Muchardt and Yaniv, 1993 (Winston and Allis, 1999) and is necessary for the stable association of the SWI/SNF complex with chromatin in vitro (Martens and Winston, 2003) . This binding, in conjunction with adherence to transcription factors, is thought to be how SWI/SNF identifies the chromatin segment with which it will associate and subsequently elicit gene expression.
BRM and BRG1 also contain an LxCxE motif [BRG1: LTCEE (1356 aa); BRM: LTCEE (1292 aa)] that is essential for binding to members of the RB tumor suppressor family . Other regions within BRG1 and BRM are also believed to facilitate RB family binding (Bourachot et al., 1999; Dahiya et al., 2000) . The ATPase domains of BRM and BRG1 are composed of helicase and DEAD box domains, which function as the motor units that convert ATP energy to mechanical movement (Muchardt and Yaniv, 1999a) . These regions are highly conserved and show a high homology with both DEAD box proteins and helicase domain in other species (Chiba et al., 1994) . Both BRG1 (210-345 aa) and BRM (255-375 aa) are highly enriched for proline residues, 35 and 21%, respectively, near their N termini. The proline-rich region in BRM is just distal to the polyQ region, which is not contained in BRG1. Both BRM and BRG1 contain B50 aa helicase/SANTassociated domains ; BRM (450-500)], which are predicted to bind DNA and are often found associated with helicases. BRG1 (170-200 aa) and BRM (168-208 aa) both contain a QLQ domain motif that has been shown to be involved in protein-protein interactions. The BRM and BRG1 genes (SMARCA2 and SMARCA4, respectively) contain about 35 exons and are subject to alternative splicing of a single exon near their C termini (Figure 3 ). The BRG1 alternatively spliced exon contains a high proportion of serine residues and may have some role in phosphorylationdependent control of the splice variant that includes this exon; however, the function of this exon remains unknown at this time. Alternative promoter utilization contributes additional regulatory variance to BRM, which is transcribed from two different promoters (Figure 3 ). Both BRM and BRG1 genes have internal promoters that give rise to carboxy-terminal truncated proteins ( Figure 3) . We have cloned and expressed cDNAs that correspond to the BGR1 C-terminal fragments (unpublished data), but the function, if any, of these proteins is unknown.
The SWI/SNF complex functions as a master regulator of gene expression SWI/SNF is a master regulator of gene expression. In mammalian cells, SWI/SNF has been linked to a large number of transcription factors. The oncogenic transcription heterodimer activated protein-1 (AP-1) is known to be SWI/SNF dependent ; similarly, EKLF, which regulates b-hemogloblin synthesis, also requires this complex for its function (Armstrong et al., 1998; Lee et al., 1999) . All known steroid receptors are functionally linked to SWI/SNF (Yoshinaga et al., 1992; Sumi-Ichinose et al., 1997; Fryer and Archer, 1998; Belandia et al., 2002; Inoue et al., 2002; Marshall et al., 2003; Flajollet et al., 2007) . SWI/SNF has been linked to CD44, CEACAM1, E-cadherin and various integrins (Liu et al., 2001; Hendricks et al., 2004; Hill et al., 2004) . It is tied to the expression of a large number of interferon (IFN)-inducible genes (Wang et al., 2005; Yan et al., 2005) . SWI/SNF has also been shown to regulate the expression of an array of genes such as c-FOS, CSF-1, CRYAB, MIM-1, p21, HSP70, vimentin, cyclindromatosis and cyclin A Liu et al., 2001; Yamamichi-Nishina et al., 2003; Hendricks et al., 2004; Wang et al., 2005) . SWI/SNF has been shown to modulate alternative splicing by creating internal 'roadblocks' to transcriptional elongation (Batsche et al., 2006) . Hence, SWI/SNF does not regulate an exclusive signaling pathway; instead, it serves as a fundamental component of various essential, and often unrelated, pathways.
The SWI/SNF complex is involved in differentiation
The SWI/SNF gene family was initially recognized because of its role in differentiation in yeast (matingtype switching) and Drosophila (pattern formation). SWI/SNF has also been strongly linked to mammalian differentiation. Transforming growth factor-b is a master regulator of cellular function and differentiation, and most transforming growth factor-b responses in human epithelial cells are dependent on BRG1 function (Xi et al., 2008) . In the early developing mouse embryo, BRG1 is expressed throughout pre-implantation development, whereas zygotic BRM is clearly detectable only when differentiation first occurs, at the blastocyst stage. BRM is restricted to the inner cell mass, and cell-typespecific expression of BRM is also observed after differentiation of embryonic stem cells (LeGouy et al., 1998) . In adult tissue, we found that BRG1 expression is predominantly seen in cell types that constantly undergo proliferation or self-renewal, whereas BRM is preferentially expressed in the brain, liver, fibromuscular stroma and endothelial cells, cell types not constantly engaged in proliferation or self-renewal (Reisman et al., 2005) .
Muscle development has been linked to the SWI/SNF complex. Myo-D, a critical master regulator of mesenchymal cell differentiation, requires SWI/SNF activity (de La Serna et al., 2001a, b; Roy et al., 2002) . BRG1 is required by geminin, Ngnr1 and Neuro-D for neuronal differentiation (Seo et al., 2005a, b) . RNAimediated knockdown of BAF60 in embryonic stem cells inhibits cardiovascular morphogenesis (Lickert et al., 2004) . A dominant-negative BRG1 allele blocks myeloid differentiation of 32Dcl3 cells (Vradii et al., 2006) , whereas loss of BRG1 in keratinocytes results in defects in limb patterning (Indra et al., 2005) . Studies in embryonic stem cells have revealed that lack of BAF250 can compromise cell pluripotency and severely inhibit self-renewal, whereas functional BAF250 contributes to the proper expression of numerous genes involved in embryonic stem cell self-renewal, including Sox2, Utf1 and Oct4 (Yan et al., 2008) (Gao et al., 2008) . Furthermore, pluripotency defects in BAF250a mutant embryonic stem cells appear to be cell lineage specific (Gao et al., 2008; Yan et al., 2008) . Thus, SWI/ SNF activity appears to be essential for differentiation in yeasts, flies and mammals. It is therefore not surprising that SWI/SNF factors are also involved in malignant transformation, an association most clearly demonstrated with the SWI/SNF subunit BAF47.
The BAF47 subunit of the SWI/SNF complex is a bona fide tumor suppressor INI1 was initially discovered as a protein that binds HIV integrase (Kalpana et al., 1994) and was later shown to be identical to the BAF47 component of the SWI/SNF chromatin-remodeling complex (Wang et al., 1996a) . The gene that encodes BAF47 is located on chromosome 22q11, a region that is frequently rearranged in pediatric rhabdoid tumors (Versteege et al., 1998) . BAF47 has been reported to undergo heterozygous deletion in both the chronic and acute phase of CML, suggesting that it plays a role in this cancer (Grand et al., 1999) . Alteration in BAF47 has also been detected in a small subset (3-4%) of Hodgkin's lymphoma patients (Yuge et al., 2000) . The strongest evidence for the role of BAF47 in cancer development comes from studies on rhabdoid tumors showing that one BAF47 allele is consistently deleted, and the other allele is either mutated or silenced by methylation (Versteege et al., 1998; Rousseau-Merck et al., 1999; Sevenet et al., 1999a, b; Biegel et al., 2000 Biegel et al., , 2002 Biegel and Pollack, 2004) . These data initially implicated BAF47 as a tumor suppressor gene. This hypothesis was subsequently confirmed by the observation that the heterozygous knockout of BAF47 (Snf5 þ /À ) in mice results in tumors that are histologically similar to human malignant rhabdoid tumors. Roberts et al. (2002) used a conditional inactivating allele to show that loss of BAF47 results in lymphomas or rhabdoid tumors with 100% penetrance within a median time of 10 weeks from birth, the most tumorigenic mouse model published to date. These observations strongly suggest that BAF47 is a bona fide tumor suppressor. However, loss of BAF47 appears to be a very rare event in human tumors (Roberts and Orkin, 2004) . Its loss occurs in both familial and sporadic renal and extra-renal rhabdoid tumors, as well as in certain central nervous system tumors (Biegel et al., 2002; Biegel and Pollack, 2004; Bourdeaut et al., 2007) ; however, not more than 50 patients have been identified with this defect, and loss of BAF47 has very infrequently been observed in any adult tumor (Grand et al., 1999; Manda et al., 2000; Yuge et al., 2000; DeCristofaro et al., 2001) . Instead, in adult tumors, the major cancer defect in SWI/SNF appears to be the loss of BRG1, BRM or both (Muchardt and Yaniv, 2001 ). This appears to occur between 10 and 20% of a variety of tumor types (Reisman et al., 2003; Glaros et al., 2007) .
SWI/SNF subunits and their role in gene regulation and cancer
The SWI/SNF complexes may be subdivided based upon their subunit composition (Figure 1 ). The BAF complexes contain BAF250 subunits, which belong to the ARID (AT-rich DNA-interacting domain) gene family. Two different genes encode BAF250 proteins. BAF250A (also known as OSA1 and p270/ARID1A) is encoded by ARID1A, whereas BAF250B (OSA2) is encoded by ARID1B (Hurlstone et al., 2002; Wang et al., 2004b) . In addition to the ARID domains, BAF250s also contain EHD1 and EHD2 domains, which map to the C termini and mediate protein binding (Hurlstone et al., 2002) . BAF250A has been linked to the functions of steroid receptors (Inoue et al., 2002) . ARID1A is located in 1p36.11 (Kozmik et al., 2001) , a region frequently deleted in human cancers (Huang et al., 2007) , and may be involved in cancer development. BAF250A is lost in two cell lines, C33a and T47D , and may be deficient in as many as 30% of renal carcinomas and 10% of breast carcinomas (Wang et al., 2004a) . ARID1A-and ARID1B-containing SWI/SNF complexes appear to have antagonistic effects on cell cycle progression, with ARID1A participating in repression and ARID1B in the induction of key cell cycle regulators such as c-MYC (Nagl et al., 2006 (Nagl et al., , 2007 . BAF180 (polybromo, PB1, PBRM1)-containing SWI/ SNF complexes have different properties from those that contain BAF250 subunits Lemon et al., 2001; Wang et al., 2004c) and are designated polybromo SWI/SNF complexes or PBAF (Figure 1 ). BAF180 harbors a distinctive set of structural motifs, characteristic of three components of RSC , another chromatin-remodeling complex in yeast. It also contains a Bromo domain that binds to acetylated histones. The BAF180 gene PBRM1 maps to chromosome 3p21, a frequent site of loss of heterozygosity in human tumors; but BAF180 has not yet been reported to be absent in cancer cells or primary tumors (Sekine et al., 2005) . BAF200 is also believed to function as part of the PBAF complex, similar to BAF180 (Yan et al., 2005) . BAF200, like BAF250, is a member of the ARID gene family and is encoded by ARID2. In addition to the ARID domain, BAF200 contains multiple LXXLL motifs (which may mediate protein-protein interaction between cofactors and nuclear hormone receptors), proline-and glutamine-rich regions, and two C2H2 Zn fingers (which may interact with either DNA or proteins) and a DNA-binding domain conserved among the regulatory factor X family of proteins (Yan et al., 2005) . Knockdown experiments indicate that BAF200 and BAF180 are required for PBAF-mediated transactivation of different sets of promoters (Yan et al., 2005) .
BAF60 is a family of three separate proteins located on different chromosomes: BAF60A, BAF60B and BAF60C (Wang et al., 1996a, b) . Each has one or more alternative transcripts that add to the complexity of the SWI/SNF complex. BAF60A has been linked to lung cancer risk (Gorlov, 2005) , binds to p53 and is necessary for steroid receptor function (Hsiao et al., 2003) . Baf60C is expressed specifically in the heart and somites in the early mouse embryo (Lickert et al., 2004) . Silencing of this gene using siRNA in mouse embryos causes defects in heart morphogenesis as well as results in abnormal cardiac and skeletal muscle differentiation (Lickert et al., 2004) Moreover, BAF60C plays a critical role in Notch-dependent transcriptional activation and in turn appears to be essential for the establishment of LR asymmetry (Takeuchi et al., 2007) . Like other SWI/SNF subunits, BAF60C has two isoforms, both of which appear to be enriched in the central nervous system and also bind to and modulate the transcriptional activity of peroxisome proliferator-activated receptor-g and the retinoic acid-related orphan receptor-a1 (Debril et al., 2004) . Both receptors have anticancer mechanisms, suggesting that the loss of the SWI/SNF function during cancer development may impair the function of these receptors.
BAF57 has a single high-mobility group (HMG) domain that displays nonspecific DNA-binding characteristics and contains a kinesin-like coiled-coil (KLCC) domain. BAF57 binds to and is required for both estrogen and androgen receptor function (Belandia et al., 2002; Link et al., 2005) . Preliminary data suggest that BAF57 may also regulate estrogen receptor expression (unpublished data), but the expression of BAF57 in primary tumors has not yet been investigated and the role of BAF57 in the etiology of ER-negative breast cancer remains to be determined.
Homozygous BAF155 knockout mice develop to early implantation stage but undergo rapid degeneration thereafter (Han et al., 2008) . About 20% of BAF155 heterozygous mutant embryos display defects in brain development, angiogenesis and visceral endoderm development in the yolk sac (Han et al., 2008) . BAF155 has been shown to stabilize BAF47, BRG1 and BAF60A by attenuating their proteosomal degradation (Sohn et al., 2007) . BAF155 may be phosphorylated by Akt, suggesting that PI3K/Akt signaling may modulate SWI/SNF function (Foster et al., 2006) . Loss of BAF155 has been reported in a small number of cancer cell lines . Moreover, BAF155 maps to 3p21-23, which is not infrequency loss in human cancers (Ring et al., 1998) .
BAF170 has a significant homology with BAF155 (Wang et al., 1996b ), 75% at the nucleotide level and 66% at the protein level. In studies involving more than 100 cell lines, this subunit has not been found to be missing or altered, so any role in cancer development thus far has not been shown . However, BAF170 maps to 12q13-15, which is frequently altered in human cancers (Ring et al., 1998) . BAF155 contains von Willebrand factor type A (vWA), SWIRM and Chromo domains, although the function of these domains in SWI/SNF activity is not well understood. BAF170 has been shown to regulate turnover of BAF57 (Chen and Archer, 2005) .
Several actin-related proteins were initially found to be constituents of the yeast SWI/SNF complex (Cairns et al., 1998; Peterson et al., 1998) . Mammalian SWI/ SNF complexes contain BAF53A (ACTL6A) and BAF53B (ACTL6B). In addition to these actin-related proteins, b-actin has also been found to be associated with the mammalian SWI/SNF complex . BAF53 binds the p53 tumor suppressor protein (Lee et al., 2005; Wang et al., 2007) , and the overexpression of an N-terminal truncated mutant of BAF53A caused cell death (Choi et al., 2001a; Lee et al., 2005) , implying an important role for BAF53 in cell survival. BAF53A is associated with mitotic chromosomes during mitosis and contributes to the internal meshwork interactions of the chromatin fiber (Lee et al., 2007a, b) . BAF53 has also been reported to shuttle between the cytoplasm and nucleus . BAF53A has also been shown to bind to c-MYC and is critical for c-MYC oncogenic activity .
The SWI/SNF ATPase subunit genes are frequently silenced in cancer
The discovery that BAF47 is a bona fide tumor suppressor gene suggests that other SWI/SNF subunits might also be tumor suppressors. We and others have examined a large number of human tumor-derived cell lines and primary tumors to determine the extent to which loss of SWI/SNF proteins occurs during transformation (DeCristofaro et al., 2001) (Muchardt and Yaniv, 2001) . Our laboratory examined a number of lung cancer and other cancer cell lines for the expression of the various SWI/SNF subunits Reisman et al., 2002) . We found that BRG1 and BRM expressions are coordinately lost in about 30-40% of lung cancer cell lines. Intriguingly, loss of either BRG1 or BRM was observed at a much lower frequency than loss of both ATPases. But both BRG1 and BRM are concomitantly lost in about 15-20% of primary nonsmall-cell lung cancers (Reisman et al., 2003; Fukuoka et al., 2004) . Analysis of more than 100 cell lines revealed that both BRG1 and BRM are lost in about 10% of established tumor cell lines . Immunohistochemical staining of tissue microarray samples has shown that BRG1 or BRM is lost in 10-20% of the bladder, colon, breast, melanoma, esophageal, head/neck, pancreas and ovarian cancers (Glaros et al., 2007 and unpublished data) . These data suggest that silencing of the SWI/SNF ATPases is involved in the etiology of a significant number and diversity of tumors.
Loss of heterozygosity occurs at the BRG1 and BRM loci
BRG1 is located in or near several microsatellite markers that demonstrate loss of heterozygosity in human cancers (Medina et al., 2004; Gunduz et al., 2005) , and the BRM locus is a site of loss of heterozygosity in human cancers as well (Eiriksdottir et al., 1995; Neville et al., 1995; An et al., 1999; Jin et al., 1999; Sarkar et al., 2002; Tripathi et al., 2003; Sabah et al., 2005) . About 26% of small-cell lung cancer cell lines and 76% of non-small-cell lung cancer cell lines have loss of heterozygosity at D9S288, which is in proximity to the BRM gene (Girard et al., 2000) . Another satellite marker, D19S221, is near the BRG1 gene, and 23% of small-cell lung cancer cell lines and 77% of non-small-cell lung cancer cell lines exhibit loss of heterozygosity at this marker (Girard et al., 2000) . Loss of heterozygosity is a hallmark of tumor suppressors, and the observation that both BRM and BRG1 loci exhibit loss of heterozygosity is consistent with the hypotheses that these two proteins function as tumor suppressors.
BRG1 is silenced by a number of mechanisms Wong et al. (2000) sequenced BRG1 exons from B180 cell lines, of which 18 cell lines were found to harbor mutations in BRG1-coding sequences. However, most of the mutations were heterozygous or were missense mutations and did not appreciably affect BRG1 expression. Similarly, Medina et al. (2008) detected mutations in 24% of lung cancer cell lines. Interestingly, this group also examined primary lung tumors with loss of heterozygosity in the BRG1 locus and did not find any appreciable mutations in these tumors (Medina et al., 2004) . Sentani et al. (2001) found no BRG1 mutations in 8 gastric carcinoma cell lines and 33 primary gastric carcinomas. Likewise, Valdman et al. (2003) reported no somatic mutations in any of the 35 BRG1 exons in samples from 21 prostate cancer patients. Gunduz et al. (2005) , who examined loss of heterozygosity at the 19p13 region in 39 oral cancers using six microsatellite markers, found allelic deletion in 25 of 39 (64%) samples; however, they did not find any mutations in either the BRG1 genomic DNA or mRNA. Although mutations in BRG1 have been detected in a variety of established cancer cell lines, such mutations have not been detected in primary tumors. As only genomic DNA has been analysed from primary tumors, other mechanisms, such as epigenetic, protein stability or translational block, probably underlie the loss of BRG1 in primary tumors. Further research will be needed to clarify this issue.
BRM is silenced by epigenetic mechanisms
Sequence analysis of BRM from 10 BRM-deficient cell lines did not reveal any mutations or other alterations that could explain why BRM is silenced (Glaros et al., 2007) . Unlike BRG1, experimental analysis by various groups has revealed that BRM is epigenetically silenced in 17 out of the 17 cell lines examined (Mizutani et al., 2002; Bourachot et al., 2003; Yamamichi et al., 2005; Glaros et al., 2007) . The observation that BRM is epigenetically silenced in cancer, rather than mutated, suggests that it might be possible to restore BRM function in tumor cells. Given that BRM is lost in B20% of a broad range of human cancers (Glaros et al., 2007) , and that the introduction of BRM into BRM-deficient cell lines causes growth arrest Muchardt and Yaniv, 1999b; Bourachot et al., 2003) , it is plausible that restoration of BRM expression might be clinically desirable. Several groups, including our own, have observed that histone deacetylase (HDAC) inhibitors can restore BRM mRNA and protein expression in a variety of BRM null cell lines (Mizutani et al., 2002; Bourachot et al., 2003; Yamamichi et al., 2005; Glaros et al., 2007) . Nuclear run-on transcription assays were used by Yamamichi et al. (2005) to show that BRM is strongly suppressed at the post-transcriptional level and that this suppression could be reversed by HDAC inhibitor treatment. Furthermore, Bourachot et al. (2003) showed that BRM overexpression inhibits the growth of K-Ras-transformed fibroblasts and that introducing HDAC inhibitors blocks this inhibitory effect of BRM. There are two carboxy-terminal acetylation sites in the BRM protein, and after the application of HDAC inhibitors, they found that the resulting acetylation of theses site abrogated the function of BRM (Bourachot et al., 2003) . Changing these sites so that they were nonacetylatable blocked the inactivation of BRM by HDAC inhibitors. Thus, nonspecific HDAC inhibitors, such as trichostatin A, butyrate and SAHA, effectively derepress BRM expression but result in the accumulation of inactive, acetylated BRM (Bourachot et al., 2003; Glaros et al., 2007) , which does not restore BRM function. There is a great deal of interest in the development of specific HDAC inhibitors, and it is possible that different HDACs may be involved in epigenetic silencing of the BRM gene and de-acetylation of the BRM protein. If this proves to be the case, then it may be possible to use specific HDAC inhibitors to induce active BRM in tumor cells.
Transgenic knockout of BRM or BRG1 enhances transformation
Transgenic knockout mouse models have been invaluable in pre-clinical investigation of the role of SWI/SNF in transformation. As cited above, the BAF47 knockout mouse is the most tumorigenic model reported to date . Knockout experiments with BRG1 and BRM have revealed that loss of either ATPase can potentiate cancer development in mice Bultman et al., 2000 Bultman et al., , 2008 Glaros et al., 2008) . However, interpretation of the results of these experiments is complicated by the possibility that BRG1 and BRM can potentially compensate for each other in certain circumstances. For example, in BRM null mice, the expression level of BRG1 is threefold higher than in wild-type BRM mice . Embryonic fibroblasts from BRM knockout mice demonstrate striking abnormalities in cell cycle control, and BRM null mice are larger than wild-type littermates Muchardt and Yaniv, 1999b; CoisyQuivy et al., 2006) . These data indicate that loss of BRM, although non-transforming, disrupts normal cell cycle control in a manner that cannot entirely be compensated for by BRG1 overexpression. In this respect, BRM null mice are primed to undergo transformation, and we have reported that BRM knockout mice contain about 10 times more lung tumors than wild-type mice when tumors are induced by the lung carcinogen urethane (Glaros et al., 2007) .
Knockout of a single allele of BRG1 results in spontaneous tumor development in about 10% of BRG1 þ /À mice within a year (Bultman et al., 2000 (Bultman et al., , 2008 . These tumors originated from the milk line and stained for histopathology markers indicative of mammary tumors. Interestingly, no alterations were noted in the remaining BRG1 allele, suggesting that these tumors arose as a result of haplo-insufficiency. In addition, the absence of BRM did not change the overall penetrance of the Brg1 þ /À tumor phenotype but may have changed the types of tumor that occur. Biallelic knockout of BRG1 is embryonically lethal (Sumi-Ichinose et al., 1997) (Bultman et al., 2000) , and until recently it has been impossible to determine the effects of BRG1 silencing in tumorigenesis. We have now developed a novel mouse model that permits conditional biallelic knockout of BRG1 in lung epithelial cells (Glaros et al., 2008) . Our data indicate that the loss of both BRG1 alleles induces apoptosis in non-transformed lung epithelial cells. BRG1 is required for the establishment and maintenance of epithelial polarity (Indra et al., 2005) , an observation that is consistent with both the pro-apoptotic effects of BRG1 knockout in the lung as well as with the early embryonic lethality of BRG1 knockout in mice. On the other hand, knockout of both BRG1 alleles in urethane-induced tumors promotes tumorigenesis (Glaros et al., 2008) . BRG1-null, urethane-induced lung tumors are more abundant, larger and have a higher index of proliferation than BRG1-positive tumors, demonstrating that the loss of BRG1 promotes tumorigenesis. Urethane is known to induce K-Ras mutations, and it is possible that loss of BRG1 in cells with oncogenic K-Ras mutations promotes tumor development, whereas loss of BRG1 in cells with wildtype K-Ras promotes apoptosis. However, this hypothesis remains to be tested.
The phenotypes of BRM
mice are strikingly different, indicating that there is much to learn about SWI/SNF function in both normal development and transformation. Our data on lung carcinogenesis in transgenic mice suggest that BRM and BRG1 may be involved in different stages of carcinogenesis (initiation versus progression) (Glaros et al., 2008) . The unresolved question is the effect of silencing or mutating the genes that encode both of the catalytic SWI/SNF subunits. Loss of both BRM and BRG1 occurs with significant frequency in many different types of solid tumors, and in lung cancer, loss of both subunits is more common than loss of either, alone (Reisman et al., 2003; Fukuoka et al., 2004) . As noted above, BAF47 knockout is the most tumorigenic defect that has been engineered to date. However, SWI/SNF activity is maintained at some level even in the absence of BAF47 (Doan et al., 2004) , which seems to function more as an enhancer of remodeling activity, rather than an obligatory component of the chromatin-remodeling complex (Phelan et al., 1999) . Conversely, concomitant loss of both BRG1 and BRM should result in the complete loss of SWI/SNF-mediated ATP-dependent chromatinremodeling activity, with attendant degradation of the several tumor suppressor functions that require SWI/ SNF. Presumably, therefore, cells that have lost both BRM and BRG1 should be highly tumorigenic. 
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; Glaros et al., 2007) and re-expression of either BRG1 or BRM inhibits growth of such cells in culture (Khavari et al., 1993; Muchardt et al., 1998) . The growth inhibitory effects of BRG1 are attenuated by the adenovirus E1A protein, which blocks the cell cycle checkpoint functions of RB family members RB1, p107 and p130. The observation that E1A blocks BRG1-mediated growth inhibition strongly suggests that SWI/ SNF activity is required for normal growth regulation by RB family members (Dunaief et al., 1994; Strober et al., 1996) , and BRG1 and BRM contain the RB-binding motif LxCxE and bind RB as well as RB family members p107 and p130 (Dunaief et al., 1994; Strober et al., 1996; Dahiya et al., 2000) . Constitutively active RB does not induce G1 arrest in cells that lack BRG1 and BRM expression (Strobeck et al., 2000 (Strobeck et al., , 2001 Zhang et al., 2000; Reisman et al., 2002) . However, restoration of BRG1 or BRM expression reconstitutes RB growth inhibition in such cells. SWI/SNF is required for E2F-dependent transcription (Trouche et al., 1997; Kang et al., 2004; Liu et al., 2004) , although all of the effects of SWI/SNF on RB checkpoint control may not require binding of BRM or BRG1 to RB. For example, re-expression of BRG1 induces p21, which inhibits RB phosphorylation by cyclin dependent kinases (CDKs) (Kang et al., 2004) . Cyclin E has been shown to bind and, in conjunction with CDK2, phosphorylate BRG1 and BAF155 (Shanahan et al., 1999; Brumby et al., 2002) . This observation raises the interesting possibility that not only does SWI/SNF regulate the cell cycle checkpoint apparatus (through RB), but also the cell cycle control machinery (through cyclin E/CDK2) may feed back to modulate SWI/SNF activity.
The p53 tumor suppressor has also been functionally linked to SWI/SNF (Lee et al., 2002; Wang et al., 2007) . p53 binds BAF53, and SWI/SNF activity is necessary for p53-mediated transcription activation and p53-mediated cell cycle control (Bochar et al., 2000; Wang et al., 2007) . It has been reported that p53-mediated cell cycle arrest is dependent upon the RB family member p130 (Claudio et al., 2000; Gao et al., 2002; Kapic et al., 2006) , which is known to bind BRG1 and BRM, and, by analogy with RB1, is likely to require SWI/SNF activity for function. Thus, the role of SWI/SNF in p53-mediated checkpoint control is likely to involve both p53 itself as well as downstream effectors of p53 signaling such as p130. Irrespective of the mechanism, it is clear that loss of SWI/SNF activity, by silencing BRM and BRG1, induces a phenocopy of a p53 loss-offunction mutation.
BRM and BRG1 are linked to DNA repair SWI/SNF complex plays an important role in DNA repair (Wuebbles and Jones, 2004; Morrison and Shen, 2006; Menoni et al., 2007; Osley et al., 2007) . DNA repair proteins such as p53, BRCA1 and Fanconi anemia proteins associate with the SWI/SNF complex and are functionally dependent on it (Bochar et al., Otsuki et al., 2001; Lee et al., 2002; Wang et al., 2007) . BRCA1 binds BRG1, and p53-mediated stimulation of transcription by BRCA1 is dependent on BRG1 (Bochar et al., 2000) . BAF47-deficient cells are hypersensitive to genotoxic stress (Klochendler-Yeivin et al., 2006) , and re-expression of BRG1 in BRG1-deficient SW13 cells renders the cells resistant to ultravioletinduced DNA damage (Gong et al., 2008) . SWI/SNF facilitates the repair of cyclobutane pyrimidine dimers (Gaillard et al., 2003) and acetylaminofluorene-guanine adducts (Hara and Sancar, 2002) in a nucleosomal context. Studies carried out in vivo indicate that SWI/ SNF is recruited to double-strand break sites (Chai et al., 2005) , and the inactivation of the SWI/SNF complex results in inefficient DNA double-strand break repair in vivo (Park et al., 2006) . These observations suggest that SWI/SNF activity (or expression of critical SWI/SNF subunits such as BRM and BRG1) may predict tumor cell susceptible to radiation and chemotherapy with DNA-damaging agents.
BRM and BRG1 control the expression of genes that are involved in cellular adhesion
When either BRG1 or BRM is restored in BRG1/BRMdeficient cell lines, cells show an increase in cell volume, area of attachment, nuclear size and growth arrest (Hill et al., 2004) . Examination of focal adhesions reveals changes in paxillin distribution, whereas increases in cell size and shape correlate with the overexpression of two integrins and the urokinase-type plasminogen activator receptor (Hill et al., 2004) . These findings suggest that SWI/SNF regulates the expression of cell-adhesion proteins and cytoskeleton structure changes. The exact genes underlying these phenomena are not completely known. However, the cell-adhesion proteins CD44 and E-cadherin are regulated by SWI/SNF (Banine et al., 2005) . CD44 transcription appears to require SWI/SNF activity, but the regulation of E-cadherin expression appears to be more complex and may involve splicing (Batsche et al., 2006) . Our preliminary data indicate that BRG1 regulates the expression of several genes that are involved in controlling Rho family GTPase activity (including RhoGDIA and IQGAP), and that these proteins may, in combination with CD44 and ERM family members, affect the stability of adherens junctions. As loss of CD44 and E-cadherin are commonly associated with transformation of epithelial cells, this aspect of SWI/SNF function warrants additional investigation. We and others have carried out preliminary microarray experiments to identify BRG1-regulated genes, and our data suggest that SWI/SNF regulates the expression of a cohort of important cell-adhesion proteins such as CEACAM1, as well as the extracellular matrix proteins such as Sparc, MMP1, MMP2, transgelin, GALS3BP P8, PODXL, Integrin A5, LGALS1, Integrin A3, TIMP3 and PLAU (Liu et al., 2001; Hendricks et al., 2004; Wang et al., 2005) . All of these interactions are known to be involved in tumor progression, and we anticipate that this aspect of SWI/ SNF function will form an important focus of future investigations in our laboratory and others.
BRM and BRG1 are required for the activity of some nuclear receptors
Steroid receptors have been functionally linked to the SWI/SNF complex (Yoshinaga et al., 1992) . In Drosophila, SWI/SNF has been shown to regulate hormoneresponsive ecdysone-induced genes (Schwartz et al., 2004; Zraly et al., 2006) . In mammalian cells, the glucocorticoid receptor has been functionally linked to the SWI/SNF complex (Muchardt and Yaniv, 1993; Ostlund Farrants et al., 1997; Trotter and Archer, 2004) , and the re-expression of either BRG1 or BRM is sufficient to restore glucocorticoid receptor function in cells that lack both BRG1 and BRM (Glaros et al., 2007) . Although it has not been investigated, the loss of BRG1 and BRM could very well underlie the resistance to glucocorticoids in hematopoietic malignancies such as myeloma, lymphoma and leukemia, as well as in lung cancer (Choi et al., 2001b; Ko et al., 2004; Pottier et al., 2007) . The estrogen receptor is also functionally linked to the SWI/SNF complex Belandia et al., 2002) , and the androgen receptor is also SWI/SNF dependent (Inoue et al., 2002; Marshall et al., 2003; Hong et al., 2005; Link et al., 2005; Dai et al., 2008) . We have found that BRG1 and BRM are lost in human prostate cancer samples, suggesting that a loss of SWI/SNF function may play a role in the development of hormone-refractory prostate cancer. It has been shown that the retinoic acid receptor is also tied to SWI/SNF (Sumi- Ichinose et al., 1997; Flajollet et al., 2007) , suggesting that the inactivation of SWI/SNF would make tumor cells refractory to clinical intervention with this reagent. As nuclear receptors are important regulators of both proliferation and differentiation, the abrogation of the SWI/SNf complex would block hormone-sensitive pathways and thereby lead to cancer progression.
BRM and BRG1 play important roles in the immune system SWI/SNF plays an important role in immune responses, T-cell development and recombination events (Golding et al., 1999; Agalioti et al., 2000; Kwon et al., 2000; Spicuglia et al., 2002; Morshead et al., 2003) . The SWI/ SNF complexes have been shown to remodel chromatin in such a way as to drive consecutive developmental transitions in T cells in response to external stimuli. Specific inactivation of SWI/SNF complexes in T cells demonstrates that such complexes are essential for thymocyte development. SWI/SNF further contributes to CD4/CD8 T-cell lineage divergence by repressing CD4 receptor expression while activating the expression of CD8 (Chi et al., 2002 (Chi et al., , 2003 Gebuhr et al., 2003) . Variable-diversity-joining (V(D)J) recombination has also been shown to be mediated by SWI/SNF. BRG1 stimulates in vitro recombination of chromatin and is also bound to regions in the T-cell receptor (TCR) and immunoglobulin loci that take part in recombination events (Golding et al., 1999; Kwon et al., 2000; Spicuglia et al., 2002; Morshead et al., 2003; Patenge et al., 2004) . More recent studies have shown SWI/SNF to be fundamental to the promoter-directed assembly of TCR-b (TCRB) genes (Osipovich et al., 2007) ; SWI/ SNF is recruited to promoters and then facilitates recombination by exposing segments of genomic DNA to V(D)J recombinase. The fact that loss of this chromatin-remodeling complex in thymocytes inactivates recombinase targets at the endogenous TCRB locus (Osipovich et al., 2007) provides further evidence for the role of SWI/SNF in recombination.
SWI/SNF also plays an important role in orchestrating IFN-induced responses. BRG1 regulates the expression of IFN-b, which is induced upon viral infection of many cell types, and is essential for innate viral immunity (Agalioti et al., 2000) . Microarray experiments have further revealed that many IFN-inducible proteins are SWI/SNF dependent (Yan et al., 2005) . BRG1 induces the expression of a subset of IFN-aactivated genes in HeLa cells (Huang et al., 2002) (Liu et al., 2002) and has been shown to be required for IFN-a to inhibit viral replication. Forced expression of BRG1 in BRM/BRG1-deficient SW13 cells leads to the upregulation of various IFN-a target genes (Liu et al., 2002) . Finally, yeast two-hybrid studies have shown that BRG1 binds to signal transducer and activator of transcription 2 (STAT2), an IFN-a-activated transcription factor (Huang et al., 2002) . Importantly, the induction of all of these genes has been shown to be inhibited when BAF47 is blocked by RNAi interference (Coisy-Quivy et al., 2006) . As a consequence of BAF47 inhibition, cellular response to viral infections and cellular antiviral activity are significantly inhibited . Thus, the tumors that lack a functional SWI/SNF may be unable to suppress viral infection and replication. As such, these tumors might become viral factories, leading to a prolonged cytokine surge by surrounding normal cells. This may be one mechanism of tumor-induced cachexia.
Major histocompatibility complex class I and II gene expression is also regulated by SWI/SNF. IFN-g induction of CIITA, the master regulator of major histocompatibility complex class II expression (Mudhasani and Fontes, 2002) , requires SWI/SNF. In addition, BRG1 also associates with the activation of the enhancer A of the major histocompatibility complex class I promoter (Brockmann et al., 2001) . Major histocompatibility complex class I and II proteins are essential for immune surveillance, and loss of SWI/SNF function could conceivably make tumors invisible to the immune system.
BRM and BRG1 exhibit partial functional redundancy
Biochemical evidence indicates that BRM and BRG1 nucleate different SWI/SNF/BAF complexes, and data from transgenic knockout mice indicate that these two complexes are not entirely redundant in their functions in vivo. BRG1 knockout mice are embryonically lethal, whereas BRM mice develop more or less normally. BRM knockout mice express very low levels of CD44, even though BRG1 levels are increased threefold in BRM null mice . Paradoxically, the re-expression of either BRG1 or BRM into BRG1/ BRM-deficient cell lines induces CD44 expression in culture (Strobeck et al., 2001; Reisman et al., 2002) . This paradox emphasizes the point that one may not be able to use transient overexpression of individual ATPase subunits to discriminate between functions that are nonredundant when BRM or BRG1 is expressed at physiological levels. Hence caution must be used in interpreting the results of experiments in which BRG1 or BRM is transiently overexpressed. Additional studies will be required to dissect the redundant and nonredundant functions of the individual ATPase subunits, which may vary in different cells depending upon the relative abundance of BRM and BRG1.
Perspectives
Broadly speaking, it is clear that the SWI/SNF complexes are required for a number of processes that are critical for cell cycle checkpoint control and differentiation. Abrogation of the normal control processes is essential for tumor growth and progression, and loss-of-function mutations in the RB and p53 pathways are among the most common oncogenic events. Mutations that affect cellular adhesion are essential for tumor progression and metastases, and other mutations are required to suppress the process of anoikis, which is normally triggered by the disruption of cellular adhesion and polarity. There is evidence that links all of these events to SWI/SNF activity, and the preponderance of data suggests that the SWI/SNF complexes function as tumor suppressors. From a mechanistic standpoint, it is clear that we have much to learn about how the SWI/SNF complexes control these processes. A critical question relates to the numerous observations that suggest that all SWI/SNF components are not equivalent in this respect. For example, loss of BAF47 is rare and is associated with a relatively small subset of tumor types, whereas loss of BRM and BRG1 is relatively common and is observed in a wide variety of solid tumors. Loss of BRM appears to predispose to tumor formation, whereas loss of BRG1 appears to be lethal in non-transformed cells, but to promote tumor progression in cells that have acquired oncogenic mutations. These observations seem to provide a rational basis for understanding why loss of both BRG1 and BRM is more common in tumors than loss of either alone. Furthermore, the connection between BRG1/BRM and tumor suppressors such as RB and p53 suggests that the loss of the SWI/SNF catalytic subunits represents an alternative route to inactivation of checkpoint control in the absence of loss-of-function mutations to the RB and p53 pathways.
Data from our laboratory and several others suggest that the etiology of 10-20% of all solid tumors is dependent upon loss of both BRM and BRG1. Such observations emphasize the need for additional studies to determine how these proteins individually and jointly impinge upon proliferation, survival and progression of tumor cells.
From a translational perspective, one is drawn to the observations (1) that the re-introduction of BRM into cells that have lost both BRM and BRG1 appears to cause terminal differentiation, or at least irreversible withdrawal from the cell cycle and (2) that BRM is epigenetically silenced and can, in theory, be induced in tumor cells. The initial work with HDAC inhibitors indicates that it may be possible to develop specific HDAC inhibitors that will induce BRM but will not result in the accumulation of inactive, acetylated BRM protein. Such drugs could have wide applicability in the treatment of tumors that have lost BRM and BRG1, and the number of such tumors is quite significant. The link between SWI/SNF activity and DNA repair is also of potential clinical interest. As loss of BRG1 appears to increase radiosensitivity of tumor cells, it is plausible that inhibitors of this ATPase could be used as adjuvants in radiotherapy. We are only now beginning to recognize the clinical potential of BRM/BRG1 as either therapeutic targets or biomarkers of chemo-or radiotherapy, and the promise of these two gene products in individualized medicine is significant.
